MedTrace Logo

Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

NCT00787826 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2021-04-29

No results posted yet for this study

Summary

This study is designed to determine the safety and immunogenicity of a Live Francisella tularensis Vaccine

Conditions

  • Tularemia

Interventions

BIOLOGICAL

Live Francisella Tularensis Vaccine

Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive "take" reaction and a MA titer of ≥ 1:20.

Sponsors & Collaborators

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • Anthony Cardile, DO · USAMRIID Medical Division

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-28
Primary Completion
2019-11-01
Completion
2021-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00787826 on ClinicalTrials.gov